IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients

Cytokine

Volumn 62, Issue 1, 2013, Pages 64-69

  Malaponte, Grazia ^a   Polesel, Jerry ^b   Candido, Saverio ^a   Sambataro, Daniela ^c   Bevelacqua, Valentina ^a   Anzaldi, Massimo ^a   Vella, Nadia ^a   Fiore, Valerio ^a   Militello, Loredana ^a,b   Mazzarino, Maria C ^a   Libra, Massimo ^a   Signorelli, Santo Salvatore ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c GARIBALDI HOSPITAL   (Italy)

Author keywords

Cancer; Deep vein thrombosis; Gene polymorphism; IL 6; MMP 9

Indexed keywords

CYTOSINE; DNA; GELATINASE B; GUANINE; INTERLEUKIN 6; THYMINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE RELEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; MALE; MMP 9 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84875811407     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.017     Document Type: Article

References (36)

1. Trousseau A, Bazire PV, Cormack JR. Lectures on clinical medicine, R. Hardwicke, London; 1867.
2. Seddighzadeh A., Shetty R., Goldhaber S.Z. Venous thromboembolism in patients with active cancer. Thromb Haemostasis 2007, 98:656-661.
3. Kakkar A.K. Cancer-associated thrombosis. Br J Cancer 2010, 102(Suppl. 1):S1.
4. Noble S., Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010, 102(Suppl. 1):S2-9.
5. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160:809-815.
6. Prandoni P., Falanga A., Piccioli A. Lancet Oncol 2005, 6:401-410.
7. Piccioli A., Prandoni P. Idiopathic venous thromboembolism as a first manifestation of cancer. Haemostasis 2001, 31:37-39.
8. Ganesh S.K., Sharma Y., Dayhoff J., Fales H.M., Van Eyk J., Kickler T.S., et al. Detection of venous thromboembolism by proteomic serum biomarkers. PLoS One 2007, 2:e544.
9. Khorana A.A., Kuderer N.M., Culakova E., Lyman G.H., Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-4907.
10. Ay C., Dunkler D., Marosi C., Chiriac A.L., Vormittag R., Simanek R., et al. Prediction of venous thromboembolism in cancer patients. Blood 2010, 116:5377-5382.
11. Kakkar A.K., Levine M., Pinedo H.M., Wolff R., Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003, 8:381-388.
12. Bennet A.M., Prince J.A., Fei G.Z., Lyrenäs L., Huang Y., Wiman B., et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003, 171:359-367.
13. Flex A., Gaetani E., Pola R., Santoliquido A., Aloi F., Papaleo P., et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg 2002, 24:264-268.
14. Iacopetta B., Grieu F., Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004, 90:419-422.
15. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
16. Libra M., Scalisi A., Vella N., Clementi S., Sorio R., Stivala F., et al. Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 2009, 34:897-903.
17. Langers A.M., Verspaget H.W., Hawinkels L.J., Kubben F.J., van Duijn W., van der Reijden J.J., et al. MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer 2012, 106:1495-1498.
18. Libra M., Signorelli S.S., Bevelacqua Y., Navolanic P.M., Bevelacqua V., Polesel J., et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006, 59:211-215.
19. Signorelli S.S., Mazzarino M.C., Di Pino L., Malaponte G., Porto C., Pennisi G., et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003, 8:15-19.
20. Breslow N.E., Day N.E. Statistical methods in cancer research volume I - the analysis of case-control studies. IARC Sci Publ 1980, 32:5-338.
21. Agnelli G. Venous thromboembolism and cancer: a two way clinical association. Thromb Haemostasis 1997, 78:117-120.
22. Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemostasis 2011, 9:316-324.
23. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
24. Fox E.A., Kahn S.R. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemostasis 2005, 94:362-365.
25. Grivennikov S., Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
26. Van Saun M.N., Matrisian L.M. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 2006, 78:69-79.
27. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
28. Gum R., Lengyel E., Juarez J., Chen J.H., Sato H., Seiki M., et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996, 271:10672-10680.
29. Zhang L.F., Mi Y.Y., Cao Q., Wang W., Qin C., Wei J.F., et al. Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Mol Biol Rep 2012, 39:3435-3441.
30. Jones K.G., Brull D.J., Brown L.C., Sian M., Greenhalgh R.M., Humphries S.E., et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265.
31. Burzotta F., Iacoviello L., Di Castelnuovo A., Glieca F., Luciani N., Zamparelli R., et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001, 88:1125-1128.
32. Giacconi R., Cipriano C., Albanese F., Boccoli G., Saba V., Olivieri F., et al. The -174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol 2004, 39:621-628.
33. Rauramaa R., Väisänen S.B., Luong L.A., Schmidt-Trücksäss A., Penttilä I.M., Bouchard C., et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2657-2662.
34. Nauck M., Winkelmann B.R., Hoffmann M.M., Böhm B.O., Wieland H., März W. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 2002, 80:507-513.
35. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., Zhang M.C., Guo D., Urbanski S.J., et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999, 94:2080-2089.
36. Greisenegger S., Endler G., Haering D., Schillinger M., Lang W., Lalouschek W., et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. Thromb Res 2003, 110:181-186.